Showing 1161-1170 of 8663 results for "".
Treatment of Psychodermatological Conditions Using N-acetylcysteine
https://practicaldermatology.com/columns/physician-spotlight/treatment-of-psychodermatological-conditions-using-n-acetylcysteine/23998/The low risk, high reward of NAC suggests its great promise in a supplementary role for treatment of trichotillomania and excoriation disorder.When Our Health Care System Injures the Physician’s Soul
https://practicaldermatology.com/topics/practice-management/when-our-health-care-system-injures-the-physicians-soul/23845/One dermatologist’s quest to protect physicians from moral injury.Diversity and Inclusion in Dermatology: The Impact of Systemic Racism in Dermatology and Opportunities for Change
https://practicaldermatology.com/issues/supplements/diversity-and-inclusion-in-dermatology-the-impact-of-systemic-racism-in-dermatology-and-opportunities-for-change/23474/Rosacea Update: A Closer Look at Zilxi
https://practicaldermatology.com/columns/clinical-focus-1/rosacea-update-a-closer-look-at-zilxi/23339/Inside the approval of Zilxi for moderate-to-severe facial papulopustular rosacea.Your Comprehensive Guide to Energy-Based Devices
https://practicaldermatology.com/topics/practice-management/your-comprehensive-guide-to-energy-based-devices/23146/A Closer Look at Skyrizi
https://practicaldermatology.com/columns/clinical-focus-1/a-closer-look-at-skyrizi/23016/The newest IL-23 blocker for psoriasis may prove to be a blockbuster, according to analysts.More Advice for Residents; AMA Calls for More Residency Slots; Call for Submissions
https://practicaldermatology.com/youngmd-connect/resident-resource-center/more-advice-for-residents-ama-calls-for-more-residency-slots-call-for-submissions/20437/Welcome 2024: Trends to Watch in Cosmetic Surgery
https://practicaldermatology.com/topics/practice-management/welcome-2024-trends-to-watch-in-cosmetic-surgery/24030/Look for noninvasive treatments, advancements in technology, and shifting age demographics.Close Up With Gil Yosipovitch, MD
https://practicaldermatology.com/columns/physician-spotlight/close-up-with-gil-yosipovitch-md/24002/DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility study